No Data
No Data
Fuan Pharmaceutical (300194.SZ): Qingyutang received the registration approval for metformin and empagliflozin tablets for the treatment of diabetes this January.
On March 4th, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) stated on the investor interaction platform that its subsidiary, Qingyutang, obtained the registration approval for metformin and empagliflozin tablets for the treatment of diabetes in January this year, but production and sales have not yet commenced.
Fuan Pharma's Unit Gets Registration Certificate for Indobufen Tablets
Fuan Pharmaceutical (300194.SZ): A subsidiary received the pharmaceutical registration certificate for Indobufen tablets.
Gelonghui reported on February 26 that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary Fuan Pharmaceutical Group Hubei Renmin Pharmaceutical Co., Ltd. (referred to as "Renmin Pharmaceutical") recently received the drug registration certificate for Indobufen Tablets issued by the National Medical Products Administration. Indobufen Tablets are suitable for ischemic cardiovascular lesions and ischemic cerebrovascular lesions caused by arteriosclerosis, as well as for venous thrombosis. They can also be used to prevent thrombosis during hemodialysis. According to the data query information platform of the National Medical Products Administration, as of now, 13 enterprises (including Renmin Pharmaceutical) have passed the consistency evaluation or equivalence.
Fuan Pharmaceutical (300194.SZ): Currently, there are no Traditional Chinese Medicine planting bases.
On February 25, Gronhg reported that Fuan Pharmaceutical (300194.SZ) stated on the investor interaction platform that its main Business is Chemical Pharmaceuticals, and there are currently no Traditional Chinese Medicine planting bases.
Fuan Pharmaceutical (300194.SZ): A subsidiary has received the pharmaceutical registration certificate for Oral Midazolam Hydrochloride Solution.
On February 10, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Hubei Renmin Pharmaceutical Co., Ltd. (referred to as "Renmin Pharmaceutical"), has recently received the drug registration certificate for oral solution of midazolam hydrochloride issued by the National Medical Products Administration. The oral solution of midazolam hydrochloride is suitable for sedation, anti-anxiety, and amnesia before and during diagnostic or therapeutic procedures in children; it can also be used for preoperative sedation, anti-anxiety, and amnesia in children. According to the data query information platform of the National Medical Products Administration, as of now, there are two enterprises (including Renmin Pharmaceutical) that have passed the approval for this drug.
Fuan Pharmaceutical (Group) Co., Ltd.'s (SZSE:300194) Share Price Is Matching Sentiment Around Its Earnings
Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough